iii

SOS Limited Announces Development of Tier III Modular Data Center at Longfellow Ranch, Texas

NEW YORK, Dec. 22, 2025 /PRNewswire/ -- SOS Limited (NYSE: SOS) ("SOS" or the "Company") announced today that it is…

2 weeks ago

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the…

3 weeks ago

Tejas Networks emerges as a leading supplier of IP Routing products across the country for BharatNet Phase III packages

BENGALURU, India, Dec. 11, 2025 /PRNewswire/ -- Tejas Networks (BSE: 540595) (NSE: TEJASNET) today announced that the company has been awarded…

3 weeks ago

Ashika Investment Managers launches Ashika Mid & Small Cap Fund, an open-ended Category III AIF

MUMBAI, India, Dec. 9, 2025 /PRNewswire/ -- Ashika Investment Managers Pvt. Ltd. has received node from SEBI for launch of…

3 weeks ago

Carl H. Sharperson III Joins MATTER Board of Directors

December 03, 2025 10:00 ET  | Source: MATTER MINNEAPOLIS, MN , Dec. 03, 2025 (GLOBE NEWSWIRE) -- MATTER, a Minnesota-based…

1 month ago

Sustainable Markets Initiative Hosts Landmark Private Capital Mobilization Convening in London, with a report back session attended by His Majesty King Charles III

LONDON, Dec. 2, 2025 /PRNewswire/ -- Yesterday, the Sustainable Markets Initiative hosted a gathering of Heads of States and Government,…

1 month ago

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)

CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases,…

1 month ago

Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment…

3 months ago

Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension

Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3In the…

4 months ago

Delska’s New 10MW Data Center in Latvia Achieves Tier III Design Certification

RIGA, Latvia, Aug. 19, 2025 /PRNewswire/ -- Northern European data center operator Delska's upcoming facility, EU North Riga LV DC1, has been…

5 months ago